What Has Been the Growth of the Budesonide Market So Far?
The budesonide market has seen considerable growth due to a variety of factors.
• In previous years, the budesonide market has witnessed robust growth. It is projected that the market will expand from $9.72 billion in 2024 to $10.36 billion in 2025, with a compound annual growth rate (CAGR) of 6.6%.
Factors such as the increasing occurrences of respiratory disorders, heightened cognizance about inhaled corticosteroids, the incorporation of combination therapies that include budesonide, the expansion of healthcare facilities and access, and the adoption of budesonide for use in cases of inflammatory bowel diseases apart from its standard applications, have all contributed to the growth during the historic years.
How Will the Budesonide Market Size In The Coming Years?
The budesonide market is expected to maintain its strong growth trajectory in upcoming years.
• The market for budesonide is poised to witness a robust expansion in the approaching years. With a projected compound annual growth rate (CAGR) of 6.3%, the size of this market is expected to surge to $13.25 billion by 2029.
This upward trajectory during the forecast period can be credited to the escalating demand for potent treatments, the rise in budesonide usage, the burgeoning elderly populace susceptible to asthma, the introduction of fresh drug delivery systems, and the proliferation of generic budesonide commodities. Major anticipated trends encompass the embracement of biologics and biosimilars, advancements in drug transportation systems, validation for innovative formulations, the establishment of ground-breaking drug delivery mechanisms, and technological progression.
What Main Forces Are Fueling Expansion In The Budesonide Market?
The surge in respiratory diseases is anticipated to fuel the expansion of the budesonide market. Respiratory diseases comprise health conditions affecting the organs and tissues necessary for gas exchange in organisms that breathe air. This surge in respiratory conditions is linked to rising air pollution, primarily exposure to particulate matter and allergens, significantly influencing the occurrence of asthma and chronic obstructive lung disease. Budesonide is utilized for respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD) to decrease inflammation, enhance airflow, and prevent symptoms such as wheezing and shortness of breath. For instance, according to the National Center for Health Statistics (NCHS), a health statistics organization based in the US, the percentage of adults over 18 years old currently suffering from asthma in the United States rose from 8.4% in 2021 to 8.7% in 2022. Moreover, the rate of asthma episodes happening in the past 12 months for adults of the same age group also increased from 3.3% in 2021 to 3.7% in 2022. Thus, the rise in respiratory disease prevalence will result in the budesonide market's growth.
What Key Areas Define The Segmentation Of The Global Budesonide Market?
The budesonide market covered in this report is segmented –
1) By Type: Inhalation Powder, Aerosols, Injectable Suspension, Tablets And Capsules
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Nose Disease Treatment, Inflammatory Bowel Disease Treatment, Respiratory Disease Treatment, Other Applications
Subsegments:
1) By Inhalation Powder: Dry Powder Inhalers (DPI), Soft Mist Inhalers (SMI)
2) By Aerosols: Metered-Dose Inhalers (MDI), Breath-Activated Inhalers
3) By Injectable Suspension: Pre-filled Syringes, Vials
4) By Tablets And Capsules: Oral Tablets, Oral Capsules
Pre-Book The Budesonide Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Budesonide Market?
Top players in the budesonide market are prioritizing advancements in respiratory care by developing oral therapies, improving patient comfort, enhancing treatment adherence, and extending therapeutic opportunities for handling asthma and other respiratory disorders. Budesonide oral therapy, a type of budesonide consumed orally, is largely used for treating inflammatory diseases. For instance, Takeda Pharmaceuticals, a pharmaceutical company based in Japan, reported in February 2024 that EOHILIA, a budesonide oral suspension, has been approved by the Food and Drug Administration (FDA), an American federal agency, as the first and sole FDA-endorsed oral drug for patients aged 11 and above dealing with eosinophilic esophagitis (EoE). Moreover, the FDA affirmed EOHILIA 2 mg to be used twice daily, based on its efficacy and safety data sourced from two multicenter, randomized, double-blind, parallel-group, placebo-controlled studies lasting 12 weeks, involving individuals aged 11 to 56 with EoE.
Who Are the Key Players In The Budesonide Market?
Major companies operating in the budesonide market are:
• AstraZeneca AB
• Novartis AG
• Takeda Pharmaceuticals Company Limited
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Sandoz AG
• Aurobindo Pharma Limited
• Chiesi Farmaceutici S.p.A.
• Cipla Limited
• Lupin Limited
• Orion Corporation
• Salix Pharmaceuticals Inc.
• Synmosa Biopharma Corporation
• Cosmo Pharmaceuticals N.V.
• Skyepharma Holdings Inc.
• Manus Aktteva Biopharma LLP
• Cennet Biopharma Private Limited
• Santarus Inc.
• SiNi Pharma Private Limited
• Shanghai Sine Promod Pharmaceutical Co. Ltd.
What Is The Most Dominant Region In The Budesonide Market?
North America was the largest region in the budesonide market in 2024. The regions covered in the budesonide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
